Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Total Debt (2017 - 2025)

Historic Total Debt for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $30.6 million.

  • Innate Pharma's Total Debt fell 1997.5% to $30.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $30.6 million, marking a year-over-year decrease of 1997.5%. This contributed to the annual value of $33.1 million for FY2024, which is 2283.5% down from last year.
  • Innate Pharma's Total Debt amounted to $30.6 million in Q2 2025, which was down 1997.5% from $33.1 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Total Debt registered a high of $50.6 million during Q4 2021, and its lowest value of $19.9 million during Q2 2021.
  • In the last 5 years, Innate Pharma's Total Debt had a median value of $42.9 million in 2023 and averaged $38.8 million.
  • Per our database at Business Quant, Innate Pharma's Total Debt tumbled by 9989.44% in 2021 and then skyrocketed by 13289.27% in 2022.
  • Innate Pharma's Total Debt (Quarter) stood at $50.6 million in 2021, then decreased by 14.85% to $43.1 million in 2022, then decreased by 0.43% to $42.9 million in 2023, then decreased by 22.84% to $33.1 million in 2024, then dropped by 7.62% to $30.6 million in 2025.
  • Its Total Debt was $30.6 million in Q2 2025, compared to $33.1 million in Q4 2024 and $38.2 million in Q2 2024.